RecruitingPhase 3NCT04799002
Topotecan and Melphalan for Retinoblastoma
Choice of Topotecan or Melphalan in Retinoblastoma Patients
Sponsor
Sun Yat-sen University
Enrollment
50 participants
Start Date
Mar 11, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Eligibility
Inclusion Criteria2
- diagnosed as retinoblastoma
- receiving eyeball-sparing treatment
Exclusion Criteria1
- disease progression during follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTopotecan
Topotecan intraocular injection for chemotherapy in retinoblastoma
DRUGMelphalan
Melphalan intraocular injection for chemotherapy in retinoblastoma
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04799002
Related Trials
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT011093945 locations
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
NCT065100101 location
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
NCT035463871 location
Retinoblastoma Phase II Expanded Access Clinical Trial
NCT066796342 locations
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT075618921 location